Aug 27, 2020 / 03:30PM GMT
Martin Welschof - BioInvent International AB - CEO
This is Martin Welschof, the CEO. First of all, welcome, everybody. Today, I'm together with Stefan Ericsson, the CFO; and Andres McAllister, Chief Medical Officer.
Before I start the presentation, just a quick word. Of course, we are all very pleased with the financing that we did over the summer period, and Stefan will cover that in more detail. And I think the most important point related to that, that's we basically have removed the financial risk for some time and can only execute on our strategy that I will explain and outline to you again in a little while.
So if you can go to the second slide, which is basically the standard forward-looking statement and then please right away to the slide number 3. And this is just to remind you a very, very quick snapshot. I will not cover all this in detail because most of this you would already know. And basically what we're doing, so we have a fully integrated discovery engine, which provides antibodies and targets, which is validated through a number of collaborations and that we are using
Q2 2020 BioInvent International AB Earnings Call Transcript
Aug 27, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers